Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of vanzacaftor + tezacaftor + deutivacaftor in children with cystic fibrosis aged 1 to 11 years
2024-513754-29-00Phase 3Authorised
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label trial of vanzacaftor, tezacaftor and deutivacaftor in cystic fibrosis (CF) (7 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Pharmacokinetic parameters of vanzacaftor, tezacaftor, deutivacaftor, and relevant metabolites, Safety and tolerability in Part A and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
vanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2024-513754-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513754-29-00.